Maurizio Zangari, MD

Research Program: Cancer Therapeutics Faculty Rank: Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Internal Medicine

Cancer Research Interest

• Disease Site Focus: Multiple Myeloma, Musculoskeletal
• Research Focus Area: Treatment, Detection, Carcinogenesis, Diagnosis/ Prognosis
• Type of Research: Clinical

Contact Information

• Email Address: MZANGARI@UAMS.EDU
• Profiles Research Networking Software: View Profile

Publications

• Mazahreh F, Mazahreh L, Schinke C, [et al., including Zangari M]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023. PMID: 36857755.
• Al Hadidi S, Dongarwar D, Schinke C, [et al., including Zangari M]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023. PMID: 36737587.
• Al Hadidi S, Szabo A, Esselmann J, [et al., including Zangari M]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2022. PMID: 36550200.
• Mohan M, Rein LE, Thalambedu N, [et al., including Zangari M]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
• Al Hadidi S, Dongarwar D, Salihu H, [et al., including Zangari M]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
• Schinke C, Poos AM, Bauer MA, [et al., including Zangari M]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single cell level. Blood advances. 2022. PMID: 35977111. PMCID: PMC9647426.
• Rasche L, Schinke C, Maura F, [et al., including Zangari M]. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nature communications. 2022 13(1):4517. PMID: 35922426. PMCID: PMC9349320.
• Alqazaqi R, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
• Gai D, Chen JR, Stewart JP, [et al., including Zangari M]. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. The Journal of clinical investigation. 2022. PMID: 35881476. PMCID: PMC9479617.
• Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA oncology. 2022. PMID: 35482363.
• Mohan M, Becnel MR, Shah UA, [et al., including Zangari M]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022. PMID: 35472167.
• Al Hadidi S, Schinke C, Thanendrarajan S, [et al., including Zangari M]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
• Abushukair H, Syaj S, Ababneh O, [et al., including Zangari M]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022. PMID: 35358350.
• Larsen K, Spencer H, Mohan M, [et al., including Zangari M]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
• Mohan M, Gundarlapalli S, Szabo A, [et al., including Zangari M]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022. PMID: 35285981.
• Mikulasova A, Kent D, Trevisan-Herraz M, [et al., including Zangari M]. Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers. Genome research. 2021. PMID: 34933939. PMCID: PMC9341503.
• Baker D, Bimali M, Carrillo L, [et al., including Zangari M]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 106(12):3215-3218. PMID: 34847659. PMCID: PMC8634177.
• Mohan M, Kendrick S, Szabo A, [et al., including Zangari M]. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood advances. 2021. PMID: 34807986. PMCID: PMC8945288.
• Baker D, Bimali M, Carrillo L, [et al., including Zangari M]. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021. PMID: 34382384.
• Yarlagadda L, Boerma M, Gundarlapalli S, [et al., including Zangari M]. Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. Cancers. 2021 13(16). PMID: 34439174. PMCID: PMC8392190.
• Boyle EM, Rosenthal A, Ghamlouch H, [et al., including Zangari M]. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021. PMID: 34365473.
• Boyle EM, Rosenthal A, Wang Y, [et al., including Zangari M]. High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. British journal of haematology. 2021. PMID: 34244996.
• Mohan M, Szabo A, Yarlagadda N, [et al., including Zangari M]. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. American journal of hematology. 2021. PMID: 34050985.
• Schinke CD, Boerma M, Bird JT, [et al., including Zangari M]. PHF19 inhibition as a therapeutic target in multiple myeloma. Current research in translational medicine. 2021 69(3):103290. PMID: 33894670. PMCID: PMC8316274.
• Mohan M, Tackett A, Kumar M, [et al., including Zangari M]. Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience. Bone. 2021 146:115876. PMID: 33556629. PMCID: PMC8627246.
• Boyle EM, Deshpande S, Tytarenko R, [et al., including Zangari M]. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nature communications. 2021 12(1):293. PMID: 33436579. PMCID: PMC7804406.
• Danziger SA, McConnell M, Gockley J, [et al., including Zangari M]. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS medicine. 2020 17(11):e1003323. PMID: 33147277. PMCID: PMC7641353.
• Deshpande S, Tytarenko RG, Wang Y, [et al., including Zangari M]. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European journal of haematology. 2020. PMID: 33107092.
• Wyeth A, Gokden N, Alapat D, [et al., including Zangari M]. Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma?. Clinical lymphoma, myeloma & leukemia. 2020 20(9):e551-e555. PMID: 32576503.
• Choudhury SR, Ashby C, Tytarenko R, [et al., including Zangari M]. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. Journal of hematology & oncology. 2020 13(1):108. PMID: 32762714. PMCID: PMC7409490.
• Tian E, Watanabe F, Martin B, Zangari M. Innate Biomineralization. International journal of molecular sciences. 2020 21(14). PMID: 32650435. PMCID: PMC7404118.
• Schinke C, Boyle EM, Ashby C, [et al., including Zangari M]. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood cancer journal. 2020 10(6):70. PMID: 32555163. PMCID: PMC7303180.
• Mohan M, Weinhold N, Schinke C, [et al., including Zangari M]. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. British journal of haematology. 2020 189(1):67-71. PMID: 31820442.
• Nishimura KK, Barlogie B, van Rhee F, [et al., including Zangari M]. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood advances. 2020 4(2):422-431. PMID: 31990333. PMCID: PMC6988393.
• Boyle EM, Ashby C, Tytarenko R, [et al., including Zangari M]. BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 31988198.
• Du Z, Weinhold N, Song GC, [et al., including Zangari M]. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood advances. 2020 4(1):181-190. PMID: 31935283. PMCID: PMC6960456.
• Radhakrishnan SV, Boyer M, Sherwin CM, [et al., including Zangari M]. A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell transplantation. 2019 28(12):1624-1631. PMID: 31619057. PMCID: PMC6923548.
• Sawyer JR, Tian E, Walker BA, [et al., including Zangari M]. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. Blood cancer journal. 2019 9(8):62. PMID: 31399558. PMCID: PMC6689064.
• Rasche L, Alapat D, Kumar M, [et al., including Zangari M]. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019 33(7):1713-1722. PMID: 30573775. PMCID: PMC6586541.
• Atrash S, Dua I, Buros AF, [et al., including Zangari M]. FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone. 2019 121:134-138. PMID: 30244157.
• Mohan M, Susanibar-Adaniya S, Buros A, [et al., including Zangari M]. Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomes. Transplant infectious disease : an official journal of the Transplantation Society. 2019 21(2):e13052. PMID: 30689291.
• Mehdi SJ, Johnson SK, Epstein J, [et al., including Zangari M]. Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. British journal of haematology. 2019 184(4):578-593. PMID: 30408155. PMCID: PMC6361704.
• Ashby C, Tytarenko RG, Wang Y, [et al., including Zangari M]. Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget. 2019 10(7):732-737. PMID: 30774775. PMCID: PMC6366829.
• Hildebrandt GC, Berno T, Gurule A, [et al., including Zangari M]. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma. British journal of haematology. 2019 184(2):308-310. PMID: 29574687.
• Rasche L, Kumar M, Gershner G, [et al., including Zangari M]. Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. Theranostics. 2019 9(16):4756-4763. PMID: 31367255. PMCID: PMC6643447.
• Morgan GJ, He J, Tytarenko R, [et al., including Zangari M]. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018 32(11):2435-2444. PMID: 29654269. PMCID: PMC6224403.
• Bennink LL, Li Y, Kim B, [et al., including Zangari M]. Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging. Biomaterials. 2018 183:67-76. PMID: 30149231.
• Zangari M, Yoo H, Shin IJ, [et al.]. Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo. Journal of bone oncology. 2018 12:19-22. PMID: 29556454. PMCID: PMC5854927.
• Rasche L, Angtuaco EJ, Alpe TL, [et al., including Zangari M]. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018 132(1):59-66. PMID: 29784643. PMCID: PMC6034645.
• Schinke C, Qu P, Mehdi SJ, [et al., including Zangari M]. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 24(12):2913-2919. PMID: 29563136.
• Davies FE, Rosenthal A, Rasche L, [et al., including Zangari M]. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica. 2018 103(6):1047-1053. PMID: 29567784. PMCID: PMC6058800.
• Zangari M, Yoo H, Shin I, [et al.]. Thymic PTH Increases After Thyroparathyroidectomy in C57BL/KaLwRij Mice. Endocrinology. 2018 159(4):1561-1569. PMID: 29381784. PMCID: PMC5839736.
• Thanendrarajan S, Tian E, Qu P, [et al., including Zangari M]. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 102(9):e364-e367. PMID: 28550191. PMCID: PMC5685226.
• Rasche L, Chavan SS, Stephens OW, [et al., including Zangari M]. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature communications. 2017 8(1):268. PMID: 28814763. PMCID: PMC5559527.
• Hoering A, Wang H, Carlton V, [et al., including Zangari M]. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 102(8):e313-e316. PMID: 28522572. PMCID: PMC5541885.
• Mohan M, Buros A, Mathur P, [et al., including Zangari M]. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. American journal of hematology. 2017 92(8):739-745. PMID: 28383130.
• Rasche L, Angtuaco E, McDonald JE, [et al., including Zangari M]. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017 130(1):30-34. PMID: 28432222. PMCID: PMC5501152.
• Jethava YS, Mitchell A, Epstein J, [et al., including Zangari M]. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 23(11):2665-2672. PMID: 27810902. PMCID: PMC6080620.
• Mohan M, Samant RS, Yoon D, [et al., including Zangari M]. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 32(6):1261-1266. PMID: 28240368. PMCID: PMC5466479.
• McDonald JE, Kessler MM, Gardner MW, [et al., including Zangari M]. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 23(8):1981-1987. PMID: 27698001. PMCID: PMC5777601.
• Sawyer JR, Tian E, Shaughnessy JD Jr, [et al., including Zangari M]. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia. 2017 31(3):637-644. PMID: 27694925. PMCID: PMC6005364.
• Chavan SS, He J, Tytarenko R, [et al., including Zangari M]. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood cancer journal. 2017 7(2):e535. PMID: 28234347. PMCID: PMC5386330.
• Weinhold N, Ashby C, Rasche L, [et al., including Zangari M]. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 128(13):1735-44. PMID: 27516441. PMCID: PMC5043128.
• Jethava Y, Mitchell A, Zangari M, [et al.]. Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6:e471. PMID: 27635734. PMCID: PMC5056975.
• Jethava Y, Mitchell A, Zangari M, [et al.]. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma. Blood cancer journal. 2016 6(7):e453. PMID: 27471869. PMCID: PMC5030385.